Study of ABT-751 in Patients With Refractory Hematologic Malignancies
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-10-09
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00047489
- Locations
- ๐บ๐ธ
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00043810
- Locations
- ๐บ๐ธ
UT MD Anderson Cancer Center, Houston, Texas, United States
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT00043823
- Locations
- ๐บ๐ธ
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
๐บ๐ธUniversity of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
IUdR/BUdR Cell Cycle Labelling
Not Applicable
Completed
- Conditions
- First Posted Date
- 2002-07-26
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00042250
- Locations
- ๐บ๐ธ
M.D. Anderson Cancer Center, Houston, Texas, United States
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
- First Posted Date
- 2002-07-19
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00041782
- Locations
- ๐บ๐ธ
UT MD Anderson Cancer Center, Houston, Texas, United States
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-06-21
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00040105
- Locations
- ๐บ๐ธ
M.D. Anderson Cancer Center, Houston, Texas, United States
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00038805
- Locations
- ๐บ๐ธ
UT MD Anderson Cancer Center, Houston, Texas, United States
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00038779
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00038818
- Locations
- ๐บ๐ธ
UT MD Anderson Cancer Center, Houston, Texas, United States
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00038857
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath